Across 22 sites in Canada, Germany, Poland, and the United States, 307 participants were randomized in a 2:1 ratio to oral semaglutide 25 mg (n=205) or placebo (n=102). Proportions meeting weight-loss targets with oral semaglutide vs placebo were 79.2% vs 31.1% for ≥5%, 63.0% vs 14.4% for ≥10%, 50.0% vs 5.6% for ≥15%, and 29.7% vs 3.3% for ≥20%. Among participants with prediabetes at baseline, 71.1% in the oral semaglutide group had normoglycemia at week 64. Gastrointestinal events were more frequent with oral semaglutide at 74.0% vs 42.2%, with nausea in 46.6% vs 18.6% and vomiting in 30.9% vs 5.9%. More information: Sean Wharton et al, Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity, New England Journal of Medicine (2025).